---
title: Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled phase II trial
euct_id: 2023-504278-39-00
phase: Phase 4
status: Recruiting
sponsor: Karolinska University Hospital
canonical_url: "https://parkinsonspathways.com/trials/eu/2023-504278-39-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2023-504278-39-00"
ctis_last_updated: "2025-07-19T03:40:22.079550216"
source: EU Clinical Trials Information System (CTIS)
---
# Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled phase II trial

**EU CT Number:** [2023-504278-39-00](https://euclinicaltrials.eu/ctis-public/view/2023-504278-39-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Karolinska University Hospital
- **Start Date:** 2023-09-01
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson's disease
- **Interventions:** Montelukast film, Madopark 100 mg/25 mg tabletter, Montelukast 30 mg placebo buccal film

## Member States

Trial is authorized in 1 member state: Sweden.

## Sites (4)

- Sahlgrenska University Hospital-Vastra Gotalandsregionen, Goteborg, Sweden
- Region Skane - Skanes Universitetssjukhus, Lund, Sweden
- Region Stockholm – SLSO, Stockholm, Sweden
- Uppsala University Hospital, Uppsala, Sweden

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2023-504278-39-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2023-504278-39-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2023-504278-39-00*